I'll retrieve comprehensive protein information for UniProtKB ID 'P08047' using the get_proteins tool to analyze O-GlcNAcylation and other post-translational modifications.I encountered an SSL certificate issue with the O-GlcNAc Database. Let me try to retrieve information about this protein using the UniProt API instead, which should provide comprehensive protein information including post-translational modifications.Now let me retrieve specific post-translational modification information for this protein to better analyze O-GlcNAcylation:Let me try without the categories parameter to get all features:Based on the comprehensive protein information retrieved for UniProtKB ID P08047 (Transcription factor Sp1), I can now provide a detailed analysis of O-GlcNAcylation and other post-translational modifications.

## Comprehensive Analysis of SP1 Protein (P08047)

### **Protein Overview**
- **Protein Name**: Transcription factor Sp1
- **Gene Name**: SP1 (synonyms: TSFP1)
- **UniProtKB ID**: P08047
- **Organism**: Homo sapiens (Human)
- **Length**: 785 amino acids
- **Function**: Key transcription factor regulating expression of genes involved in cell growth, apoptosis, differentiation, and immune responses

### **O-GlcNAcylation Sites and Extent**

The protein shows significant O-GlcNAcylation with **5 confirmed O-linked GlcNAc sites**:

1. **Serine 491** - O-linked (GlcNAc) serine (confirmed in transactivation domain B)
2. **Serine 612** - O-linked (GlcNAc) serine; alternate (in transactivation domain C)
3. **Threonine 640** - O-linked (GlcNAc) threonine; alternate (near zinc finger region)
4. **Serine 641** - O-linked (GlcNAc) serine; alternate (near zinc finger region)
5. **Serine 698** - O-linked (GlcNAc) serine; alternate (in domain D)
6. **Serine 702** - O-linked (GlcNAc) serine; alternate (in domain D)

### **Other Post-Translational Modifications**

**Phosphorylation** (extensive):
- Multiple serine and threonine phosphorylation sites (Ser-2, Ser-7, Ser-59, Ser-101, Thr-278, Thr-453, Thr-739, etc.)
- Mediated by various kinases including MAPK1/3, MAPK8, ATM, PKC/PRKCZ

**Acetylation**:
- N6-acetyllysine at position 703
- Affects transcriptional activity through p300 recruitment

**SUMOylation**:
- Lysine 16 can be SUMOylated with SUMO1 or SUMO2
- Modulates proteolytic cleavage and transcriptional activity

**Ubiquitination**:
- Occurs on C-terminal peptide, triggered by phosphorylation

### **Functional Impact of O-GlcNAcylation on Metabolic Pathways**

#### **1. Insulin Signaling and Glucose Metabolism**
- **Insulin-mediated regulation**: The UniProt data indicates that "insulin promotes nuclear location" and "levels are controlled by insulin and SP1 phosphorylation states"
- **O-GlcNAcylation contains 8 N-acetylglucosamine side chains** and is insulin-responsive
- **Sequential modification**: "On insulin stimulation, sequentially glycosylated and phosphorylated on several C-terminal serine and threonine residues"

#### **2. Nuclear-Cytoplasmic Shuttling**
- **Location control**: "Nuclear location is governed by glycosylated/phosphorylated states"
- **Hormonal regulation**: "Insulin promotes nuclear location, while glucagon favors cytoplasmic location"
- This suggests O-GlcNAcylation acts as a metabolic sensor, directing SP1 subcellular localization based on nutrient status

#### **3. Transcriptional Activity Modulation**
- **Protein interactions**: O-GlcNAcylation "affects transcriptional activity through disrupting the interaction with a number of transcription factors including ELF1 and NFYA"
- **Inhibitory effects**: "Also inhibits interaction with the HIV1 promoter"
- **Competition with phosphorylation**: Several sites show "alternate" O-GlcNAcylation/phosphorylation, indicating dynamic competition between these modifications

#### **4. Metabolic Gene Regulation**
- **BMAL1 regulation**: SP1 "positively regulates the transcription of the core clock component BMAL1," linking it to circadian metabolism
- **VEGF pathway**: MAPK-mediated phosphorylation "enhances VEGF transcription but represses FGF2-triggered PDGFR-alpha transcription"

### **Clinical and Therapeutic Implications**

#### **1. Diabetes and Metabolic Disease**
- The extensive O-GlcNAcylation and insulin responsiveness suggest SP1 is a key node in glucose sensing
- Dysregulated O-GlcNAcylation could contribute to diabetic complications

#### **2. Cancer**
- **Overexpression**: "Up-regulated in adenocarcinomas of the stomach"
- **Telomerase activation**: "maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression"

#### **3. Oxidative Stress Response**
- SP1 plays "a role in protecting cells against oxidative stress following brain injury"

### **Sequence Information**
The protein sequence (785 aa) contains multiple functional domains:
- Repressor domain (2-82)
- Three transactivation domains (A: 146-251, B: 261-495, C: 496-610)
- Three C2H2-type zinc fingers (626-650, 656-680, 686-708)
- Domain D (708-785)

### **Conclusion**

SP1 represents a highly modified transcription factor where O-GlcNAcylation serves as a critical metabolic sensor. The modification pattern suggests that O-GlcNAcylation coordinates with phosphorylation to regulate SP1's nuclear localization, protein interactions, and transcriptional activity in response to metabolic signals like insulin and glucose availability. This makes SP1 a key integration point between cellular metabolism and gene expression, with significant implications for metabolic diseases and cancer.